Christopher Viehbacher

President, Chief Executive Officer & Director, Biogen

Search every verified Christopher Viehbacher interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. On Biogen's first quarter 2025 earnings call, Christopher Viehbacher described the company as "a tale of two companies," noting that its multiple sclerosis portfolio has been "gradually declining" while a "new Biogen" is emerging. He stated that the company's actively promoted commercial portfolio, including rare disease drugs and Alzheimer's treatments, now accounts for about 45% of product revenue. Viehbacher called Leqembi "the first disease modifying agent that has ever been approved in Alzheimer's" and said that having regulatory endorsement is "extremely important." Viehbacher said Biogen does not expect a material impact in 2025 from potential tariffs, even if the pharmaceutical exemption were removed, citing U.S.-based manufacturing and global inventory positions. He noted that Biogen is open to partnering on excess manufacturing capacity, mentioning that its Solothurn facility is doing contract development and manufacturing organization (CDMO) business and that its Research Triangle Park facility already manufactures for third parties. He also stated that Biogen has a goal of signing four to five new research collaborations in 2025.